Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial

Summary: Background: Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo c...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	James H. McMahon, Jillian S.Y. Lau, Anna Coldham, Janine Roney, Michelle Hagenauer, Sally Price, Mellissa Bryant, Jill Garlick, Anne Paterson, Sue J. Lee, Jess O'Bryan, Anna Hearps, Gilda Tachedjian, Henry Pinskier, Cameron Phillips, Stuart Garrow, Nathan Pinskier, Robert Melvin, Luke Blakeway, Jessica A. Wisniewski, Sally Byers, Gnei Z. Badoordeen, Stephanie Pereira, Katherine Pragastis, Jason A. Trubiano, Kyra Y.L. Chua, Marion Kainer, James S. Molton, Bradley J. Gardiner, Anna B. Pierce, Allen Cheng, Benjamin A. Rogers, Anton Y. Peleg
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2022-12-01
Serier:	EClinicalMedicine
Fag:	Favipiravir COVID-19 Randomised clinical trial
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2589537022004333
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!